Short Communication
Volume 1 Issue 1 - 2015
Stability Indicating Assay Method Development and Validation of Tolteridone Tartrate in Bulk Drug and Capsules
V Asha Ranjani1*, T Prabhakar2 and Girija Sankar2
1Department of Pharmaceutical Analysis, MLR Institute of Pharmacy, India
2Department of Biotechnology, AU College of Pharmaceutical Sciences, India
*Corresponding Author:V Asha Ranjani, MLR Institute of Pharmacy, India.
Received: January 10, 2015; Published: January 31, 2015
Citation: V Asha Ranjani., et al. “Stability Indicating Assay Method Development and Validation of Tolteridone Tartrate in Bulk Drug and Capsules”. EC Pharmaceutical Science 1.1 (2015): 44-49.
Abstract
A stability indicating novel RP-HPLC method as developed for the quantification of Tolteridone tartrate in capsules. The separation was carried out by Athena C18 (250 mm × 4.6 mm) 5µ column using mobile phase phosphate buffer (pH 4.0), acetonitrile and methanol in the ratio of 40:20:40 v/v at a flow rate of 1 ml/min and detection at 240 nm. The retention time of Tolteridone tartrate was found to be 2.417 min and standard calibration plot was linear over a concentration range of 60-140 µg/ml with r2 0.999. The method has been validated for accuracy, specificity, precision, robustness and ruggedness. Forced degradation studies were conducted according to ICH guidelines. The assay and recoveries of the drug was found to be 99.4% and 99.8 ± 0.2%.
Keywords: Stability studies; Tolteridone tartrate (TOL); Capsules, RP-HPLC
Tolteridone tartrate is a muscarinic receptor antagonist and it chemically described as (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine–L-hydrogen tartrate. It exists in two isomeric forms (R) and (S) [1]. It is used in the treatment of urinary urge incontinence and other symptoms of an overactive bladder [2]. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, Tolteridone is metabolized in the liver, resulting in the formation of the 5-hydroxy methyl derivative, a major pharmacologically active metabolite. The 5-hydroxy methyl metabolite, which exhibits an antimuscarinic activity similar to that of Tolteridone contributes significantly to the therapeutic effect. Both Tolteridone and 5-hydroxy methyl metabolite exhibit a high specificity for muscarinic receptors, either both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels [3]. Literature studies indicated [4] a variety of analytical methods for analysis of drug in biological matrices, for example HP-electrospray ionization mass spectrometry (LC-ESI-MS), capillary solid phase extraction (SPE) coupled with electrospray tandem mass spectrometry and GC-MS. A variety of few methods have been reported for the determination of Tolteridone in formulations by UV-Spectrophotometry and HPLC [5]. But limited methods investigated for the determination of Tolteridone from its tablets or its pharmaceutical dosage form. As per ICH guidelines stability is a fundamental property of all products and the term "stability indicating assay" had been used describe a procedure which affords specific determination of a drug substance in the presence of its degradation products. The prime objective of studying the stability [6] of drug is to determine its shelf life. The various stress conditions specified for forced degradation studies include thermal, light, acidic, alkaline, hydrolysis and oxidative stress. Limited work was done on the stress studies of Tolteridone tartrate [7]. So an attempt was made to develop and validate a simple, precise, accurate and economical RP-HPLC method as per ICH guidelines.
Figure 1: Chemical structure of Tolteridone tartrate.
Tolteridone tartrate of pharmaceutical grade was supplied as gift sample by Aurobindo Pharma, Hyderabad. TOL capsules were procured from local market. Acetonitrile, methanol and ammonium di hydrogen orthophosphate of HPLC grade were purchased from S.D fine chemicals Hyderabad. Liquid chromatography used was Schimadzu LC-2010 equipped with autosampler and photo diode array detector [8]. The chromatographic analysis was performed using LC solution software on Athena C 18 column (250 mm × 4.6 mm) 5µ column. In addition, digital micro balance electrolab and pH meter were used in this study. A mixture of phosphate buffer (pH 4.0), acetonirile and methanol in the ratio of 40:20:40 v/v was used as mobile phase and filtered through a 0.45 µm membrane filter and degassed. Flow rate was maintained at 1.0 ml/min with the detection at 240 nm.
Standard stock solution of TOL (100 µg/ml) was prepared by dissolving 100 mg of TOL with the mobile phase in 100 ml flask and further dilution was done by transferring 5ml of the solution in to 50ml flask and make up the volume with mobile phase. Twenty five capsules of Urotel-X each containing 4mg of TOL were weighed, empty the capsules and finely powdered. A quantity of powder equivalent to 100 mg of TOL [9] was transferred to 100 ml flask and make up the volume with mobile phase, which contain concentration of 100 µg/ml. Both the standard and stock solutions were filtered through 0.45µ membrane filter. An aliquot of 20 µl of both standard and stock solutions were injected separately and chromatograms were recorded up to 10 min. Standard stock solutions in the concentration range of 60, 80, 100, 120 and 140 mcg were prepared. Five series of standard solutions containing 0.6 to 1.4 ml of standard stock solutions and make up to 10 ml with the mobile phase. The solutions were injected using a 20 µl and chromatograms were recorded. Calibration curves [10] were constructed by plotting peak area versus concentration and regression equations were computed for the drug.
Figure 2: A typical HPLC chromatogram of pure Tolteridone tartrate.
Figure 3: A typical HPLC chromatogram of Tolteridone tartrate in sample formulation.
Figure 4: Linearity of Tolteridone tartarate.
The method of analysis was validated as per the guidelines of ICH and USP for the parameters like specificity, accuracy, linearity, precision, limit of detection, limit of quantitation, robustness and ruggedness. Forced degradation studies of the bulk drug carried out under conditions of acid, alkali, thermal, oxidation and UV. For heat and light study period was 10 days where as for acid, base and oxidative degradation it was about 48 hrs. There is no significant degradation of the sample was obtained in the acid, alkali, thermal, oxidation and UV [11]. In method precision, a homogenous sample of a single batch was analyzed six times and was checked whether the method gave consistent results for a single batch. The sample TOL was analyzed six times of the same batch as per analytical procedure. The % relative standard deviation was calculated. The % RSD of the TOL for six determinations was found to be 0.63% which is within the acceptance criteria limit and it is concluded that the method is precise. The system precision was carried out to ensure that the analytical system was working properly. Standard solution was injected six times in to the system and chromatogram was recorded. The % RSD [12] was found to be 0.29%.
Accuracy was investigated by spiking the drug with the sample at three different concentration levels i.e 80, 100 and 120%. The recovery obtained was in the range of 99.8 to 100.2% demonstrating that the method proposed is highly accurate. Percent recoveries for the marketed products were found to be within the acceptable limits. The robustness of an analytical method is a measure of its capacity to remain unaffected by small but deliberate variations in method parameters. The standard solutions were injected in to the chromatogram at slight changes of flow and wavelength. The effectiveness of the deliberated changes was observed on retention time of peak [13]. The statistical data gives no significant variations in the above parameters indicating the method is robust. Ruggedness was performed by injecting same concentrations of standard and sample solutions, which were prepared and analyzed by different analyst. It is also expressed in terms of percentage recoveries of the drug. It was obtained as 98.5% and 99.2%, indicating that less variation of assay by two analysts. Range is the minimum and maximum concentration of sample at which the analytical procedure gives reproducible results. It can be determined by linearity, accuracy and precision studies [14]. The method was found acceptable across wide range of concentration 60-140 µg/ml. The limit of detection is the minimum concentration of the analyte that gives a measurable response; whereas limit of quantification is the minimum concentration that can be quantified accurately and precisely.
Parameters Tolteridone tartrate
Linearity range (mg/ml) 0.06 to 0.14
Correlation coefficient (r2) 0.9999
Slope (m) 6.866
Intercept  (c) 38.08
LOD 15.20 mcg/ml
LOQ 46.06 mcg/ml
Tailing factor  (T) 1.611
Retention time (min) 2.417
Theoretical plates 4355
(%) RSD 0.63
(%) Accuracy 100.4
(%) Assay 99.4
Table 1: Validation parameters of Tolteridone tartrate.
Conclusion
In the proposed research study, stability of TOL was established based on tests utilizing ICH recommended stress conditions. Mild degradation was observed in acidic, alkali, thermal, light and oxidation conditions. Drug peak was well resolved from the peak of its degradation products as well as those of excipients in formulation. The validated method yielded good results of precision, linearity, accuracy and robustness. The proposed research study was found to be suitable and accurate for the method development and validation of TOL in pharmaceutical formulations. Statistical result and low % RSD values indicate that the method can be used for routine analysis of the drug.
Bibliography
  1. Kumar YR., et al. “A validated chiral HPLC method for the enantiomeric separation of tolterodine tartarate”. Journal of pharmaceutical and biomedical analysis 35.5 (2004): 1279-1285.
  2. Chapple CR., et al.“The effects of antimuscarinic treatment in overactive bladder” European Urology 54.3 (2008): 543-562.
  3. Nilvebrant L., et al. “Tolteridone-a new bladder selective muscarinic agent”. European Journal of pharmacology 327.2-3 (1997): 195-207.
  4. Ramathilagam N., et al.“Development and validation of HPLC method for the estimation of Tolteridone tartrate in tablets”. International Journal of Pharma and Bio Sciences 2.4 (2012): 332-337.
  5. Shanmugakumar SD., et al. “A simple method development and validation of Tolteridone tartrate and Tamsulosin hydrochloride by RP-HPLC method”. Indo American Journal of Pharmaceutical Research 3.10 (2013): 8169-8177.
  6. Saxena V., et al. “Stability-indicating HPLC determination of tolteridone tartrate in pharmaceutical dosage form”. International Journal of Chemical Technology 13.3 (2006): 242-246.
  7. Ramesh Yanamandra., et al. “A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human plasma, and Urine Samples”. Scientia Pharmaceutica 80.1 (2012): 101-114.
  8. Ravinda KN., et al. “Simultaneous spectroscopic estimation of tolteridone in pharmaceutical dosage form”. Journal of Pharmacy Research 2 (2009): 312-314.
  9. Silverstein RM., et al. “Spectrometric Identification of Organic compounds”. John Willey and Sons, Inc, New York, 1991.
  10. Pavia DL., et al. “Introduction to Spectoscopy”. 3rd ed. Thomson Learning Inc, USA, 2001.
  11. Bakshi M and Singh S. “Development of validated stability indicating assay methods-Critical review”. Journal of Pharmaceutical and Biomedical Analysis 28.6 (2002): 1011-1040.
  12. International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for Human use. Specifications: Test procedures and acceptance criteria for new drug substances and new drug products. Chemical Substances Specification for test procedure guidelines. Geneva; Q6A; 1996.
  13. Watson JT and Spakman OD. "Introduction to Mass Spectrometry". John Willey and Sons, Ltd. Sussex, England, 2007.
  14. Mach J. “Advanced Organic Chemistry, Reactions, mechanisms and structures”. John Wiley and Sons. Wiley India (P), New Delhi, India 2005.
  15. Baertschi SW. “Pharmaceutical stress Testing, Predicting Drug Degradation”. Taylor and Francis Group, FL, USA, 2005.
Copyright: © 2015 V Asha Ranjani., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events

August Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the August issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for September Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the September issue of respective journals. Submissions are accepted on/before August 15, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk